Cerberus Ventures led a $33m Series A round in Syntis.

Cerberus Ventures, a venture capital arm of Cerberus Capital Management, led a $33m Series A round in Syntis, a clinical-stage biopharmaceutical company, with participation from Mansueto Investments, Woori Venture Partners, Apollo Labs, BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures and Cerity Partners Ventures. "We are grateful for the continued support and enthusiasm of our new and existing investors, who share our vision to revolutionize both chronic and rare disease treatment through safe, effective oral therapies," Rahul Dhanda, Syntis CEO and Co-Founder.